Suven Pharmaceuticals Limited
Suven Pharmaceuticals Limited, a prominent player in the pharmaceutical industry, is headquartered in Hyderabad, India. Founded in 1989, the company has established itself as a leader in the development of innovative drug discovery and development services, particularly in the fields of central nervous system disorders and other therapeutic areas. With a strong focus on research and development, Suven Pharmaceuticals offers a diverse portfolio of products, including proprietary drug candidates and contract research services. The company is recognised for its unique approach to drug development, leveraging advanced technologies to enhance therapeutic efficacy. Suven's commitment to quality and innovation has positioned it favourably in the global market, earning accolades for its contributions to healthcare and significant milestones in clinical research. As it continues to expand its operational footprint, Suven Pharmaceuticals remains dedicated to improving patient outcomes through cutting-edge pharmaceutical solutions.
DitchCarbon Score
How does Suven Pharmaceuticals Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Suven Pharmaceuticals Limited's score of 34 is higher than 89% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Suven Pharmaceuticals Limited's reported carbon emissions
In 2023, Suven Pharmaceuticals Limited reported total carbon emissions of approximately 48,594,000 kg CO2e from Scope 1 and 33,723,000 kg CO2e from Scope 2, totalling about 82,317,000 kg CO2e. This represents a slight increase in emissions compared to 2022, where emissions were approximately 47,497,790 kg CO2e for Scope 1 and 35,462,000 kg CO2e for Scope 2, totalling around 82,959,790 kg CO2e. Suven Pharmaceuticals has committed to achieving net-zero emissions by 2050, aligning with the Science Based Targets initiative (SBTi). This long-term commitment encompasses all scopes of emissions, reflecting the company's dedication to addressing climate change within the pharmaceutical sector. The company is actively working towards this goal, having initiated its reduction strategy in 2023. As part of its climate commitments, Suven Pharmaceuticals is focused on reducing its carbon footprint and enhancing sustainability practices across its operations. The company continues to monitor and report its emissions, aiming for transparency and accountability in its environmental impact.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | 2024 | |
|---|---|---|---|
| Scope 1 | 47,497,790 | 00,000,000 | 00,000,000 |
| Scope 2 | 35,462,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Suven Pharmaceuticals Limited is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
